Governor Cuomo says that controlling the cost of prescription drugs will be part of his agenda in 2020. Four bills currently awaiting his signature or veto give him a chance to get started on that promise in 2019.
Federal officials are reviewing the state's expropriation of $2 billion from the sale of Fidelis Care health plan, potentially throwing a wrench into the Cuomo administration's plans for using the money.
Is the Cuomo administration disclosing its payouts from the $2 billion Health Care Transformation Fund as required law? You be the judge.
New York's employer-sponsored health insurance premiums – which were already among the steepest in the mainland United States – rose faster than the national average in 2018, pushing the state's affordability gap to new heights.
De Blasio’s claim was “very misleading,” said Bill Hammond, the health policy director at the Empire Center for Public Policy, a nonpartisan, New York-focused think tank. Voters might think he is referring to universal insurance or even a single-payer system, he said, neither of which is true.
Dozens of the health-care bills percolating through the Legislature in the closing days of session have one thing in common: They would add to the already high price of health insurance in New York State.
The balance of unspent money in the Essential Plan Trust Fund ballooned to a new high of $1.2 billion as of March 31, records from the comptroller's office show. The surplus more than tripled since the same time last year – even as the Trump administration disrupted federal aid for the program, which provides health coverage to low-income New Yorkers, and the Cuomo administration diverted $635 million in Essential Plan funds to subsidize struggling hospitals.
Sen. Kirsten Gillibrand has apparently doubled the price tag of her Medicare buy-in proposal, from 4 percent of income to 8 percent – but the math still does not add up.